The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.

The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

The disclosure relates to olefin oligomerization processes and related zeolites and structure directing agents. The olefin oligomerization processes can exhibit relatively high conversions. The zeolites can exhibit comparatively high stabilities. The zeolites can have relatively high ratios of external surface area to total surface area. An exemplary zeolite is a beta zeolite having a relatively high ratio of external surface area to total surface area. The disclosure also relates to structure directing agents, and methods of using the structure direction agents to prepare the zeolites.

This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R.sub.1-R.sub.6 are as defined herein.

##STR00001##

This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R.sub.1-R.sub.6 are as defined herein.

##STR00001##

The present disclosure relates to novel compounds, and pharmaceutical compositions thereof, useful for treating for treating neurodegenerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed. Representative members of these compounds include: ##STR00001##

The present invention relates to a modification polymerization initiator and a method for preparing the same, and the modification polymerization initiator includes a derived unit from a compound represented by Formula 1 and may include various functional groups in a molecule, and thus, may initiate polymerization reaction and introduce a functional group into a polymer chain at the same time.

A method of promoting the differentiation of an oligodendrocyte precursor cell is disclosed herein. The method includes administering to the oligodendrocyte precursor cell an effective amount of a compound capable of promoting oligodendrocyte precursor cell differentiation. Also disclosed herein is a method of treating a neurodegenerative disorder, including a demyelinating disease such as multiple sclerosis, in a subject in need thereof, comprising administering to the subject a compound disclosed herein.

A method of promoting the differentiation of an oligodendrocyte precursor cell is disclosed herein. The method includes administering to the oligodendrocyte precursor cell an effective amount of a compound capable of promoting oligodendrocyte precursor cell differentiation. Also disclosed herein is a method of treating a neurodegenerative disorder, including a demyelinating disease such as multiple sclerosis, in a subject in need thereof, comprising administering to the subject a compound disclosed herein.